<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased bone marrow <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and vascular endothelial growth factor (VEGF) levels are adverse prognostic features in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) </plain></SENT>
<SENT sid="1" pm="."><plain>VEGF is a soluble circulating angiogenic molecule that stimulates signaling via receptor tyrosine kinases (RTKs), including VEGF receptor 2 (VEGFR-2) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts may express VEGFR-2, c-kit, and FLT3 </plain></SENT>
<SENT sid="3" pm="."><plain>SU5416 is a small molecule RTK inhibitor (RTKI) of VEGFR-2, c-kit, and both <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant FLT3 </plain></SENT>
<SENT sid="4" pm="."><plain>A multicenter phase 2 study of SU5416 was conducted in patients with refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>For a median of 9 weeks (range, 1-55 weeks), 55 patients (33 AML: 10 [30%] primary refractory, 23 [70%] relapsed; 22 MDS: 15 [68%] relapsed) received 145 mg/m2 SU5416 twice weekly intravenously </plain></SENT>
<SENT sid="6" pm="."><plain>Grade 3 or 4 drug-related toxicities included <z:hpo ids='HP_0002315'>headaches</z:hpo> (14%), infusion-related reactions (11%), <z:hpo ids='HP_0002094'>dyspnea</z:hpo> (14%), <z:mp ids='MP_0002899'>fatigue</z:mp> (7%), thrombotic episodes (7%), <z:hpo ids='HP_0002653'>bone pain</z:hpo> (5%), and gastrointestinal disturbance (4%) </plain></SENT>
<SENT sid="7" pm="."><plain>There were 11 patients (20%) who did not complete 4 weeks of therapy (10 progressive disease, 1 adverse event); 3 patients (5%) who achieved partial responses; and 1 (2%) who achieved hematologic improvement </plain></SENT>
<SENT sid="8" pm="."><plain>Single agent SU5416 had biologic and modest clinical activity in refractory <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Overall median survival was 12 weeks in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients (range, 4-41 weeks) and not reached in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="10" pm="."><plain>Most observed toxicities were attributable to drug formulation (polyoxyl 35 castor oil or hyperosmolarity of the SU5416 preparation) </plain></SENT>
<SENT sid="11" pm="."><plain>Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
</text></document>